| Next 10 |
Ad
CTIC News and Press CTI BioPharma Corp.
-
CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting PR Newswire SEATTLE , Sept. 21, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announ...
-
CTIC announced its 2Q 2022 results on 8 August. With booked revenues coming in at $12.3 million for the quarter, revenues were above Street expectations. In my view, the 26% share price decline since the results is a reaction to BVF Partners (a major equity holder of the company) sell...
-
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...
-
A big revenue beat couldn't make up for a modest bottom-line miss on Tuesday for CTI BioPharma (NASDAQ: CTIC) . Shares of the commercial-stage biotech took a nearly 12% hit on the day, as investors signaled their disapproval of the company's latest set of quarterly results. CTI ...
-
CTI BioPharma Corp. (CTIC) Q2 2022 Earnings Conference Call August 08, 2022 04:30 PM ET Company Participants Adam Craig - Chief Executive Officer & President Jim Fong - Chief Commercial Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief O...
-
CTI BioPharma press release ( NASDAQ: CTIC ): Q2 GAAP EPS of -$0.21 misses by $0.01 . Revenue of $12.33M beats by $3.23M . For further details see: CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M
-
CTI BioPharma Reports Second Quarter 2022 Financial Results PR Newswire – VONJO ® (pacritinib) net product revenue of $12.3 million in the second quarter – – Management to host conference call today at 4:30 p.m. ET –...
-
Major earnings expected after the bell on Monday include: 3D Systems ( DDD ) Lemonade ( LMND ) Novavax ( NVAX ) Take-Two Interactive Software ( TTWO ) Upstart Holdings ( UPST ) For further details see: Notable earnings after Monday's close...
-
CTI BioPharma to Report Second Quarter 2022 Financial Results on August 8, 2022 PR Newswire – Company Also Announces Participation in the BTIG Biotechnology Conference and the Stifel Biotech Summer Summit – SEATTLE , Aug. 1, 2022 /PR...
-
CTI BioPharma has finally fulfilled its long sought goal of FDA approval for its VONJO (JAK inhibitor pacritinib) in treatment of myelofibrosis. Armed with a wholesale cost of ~$19,500 month, VONJO could be a blockbuster. CTI's market cap of ~$0.681 leaves room for upside if it ca...
Stock Information
MENU
CTIC
CTIC Quote
CTIC Short
CTIC News
CTIC Articles
Get CTIC Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
-
CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting PR Newswire SEATTLE , Sept. 21, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announ...
-
A big revenue beat couldn't make up for a modest bottom-line miss on Tuesday for CTI BioPharma (NASDAQ: CTIC) . Shares of the commercial-stage biotech took a nearly 12% hit on the day, as investors signaled their disapproval of the company's latest set of quarterly results. CTI ...
-
CTI BioPharma Reports Second Quarter 2022 Financial Results PR Newswire – VONJO ® (pacritinib) net product revenue of $12.3 million in the second quarter – – Management to host conference call today at 4:30 p.m. ET –...